Roberto Pili

  • 11420 Citations
  • 53 h-Index
1987 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Publications

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature

Gotink, K. J., Broxterman, H. J., Honeywell, R. J., Dekker, H., de Haas, R. R., Miles, K. M., Adelaiye, R., Griffioen, A. W., Peters, G. J., Pili, R. & Verheul, H. M. W., 2014, In : Oncoscience. 1, 12, p. 844-853 10 p.

Research output: Contribution to journalArticle

21 Scopus citations

Active ageing and success: A brief history of conceptual models

Petretto, D. R., Pili, R., Gaviano, L., Matos López, C. & Zuddas, C., Nov 28 2014, (Accepted/In press) In : Revista Espanola de Geriatria y Gerontologia.

Research output: Contribution to journalArticle

9 Scopus citations

Active smokingmay negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treatedwith sunitinib

Keizman, D., Gottfried, M., Ish-Shalom, M., Maimon, N., Peer, A., Neumann, A., Hammers, H., Eisenberger, M. A., Sinibaldi, V., Pili, R., Hayat, H., Kovel, S., Sella, A., Boursi, B., Weitzen, R., Mermershtain, W., Rouvinov, K., Berger, R. & Carducci, M. A., Jan 22 2014, In : Oncologist. 19, 1, p. 51-60 10 p.

Research output: Contribution to journalArticle

35 Scopus citations

Adenovirus-mediated gene transfer of fibroblast growth factor-1: Angiogenesis and tumorigenicity in nude mice

Pili, R., Chang, J., Muhlhauser, J., Crystal, R. G., Capogrossi, M. C. & Passaniti, A., Oct 29 1997, In : International Journal of Cancer. 73, 2, p. 258-263 6 p.

Research output: Contribution to journalArticle

7 Scopus citations

Adenovirus‐mediated gene transfer of wild‐type p53 results in melanoma cell apoptosis in vitro and in vivo

Cirielli, C., Riccioni, T., Yang, C., Pili, R., Gloe, T., Chang, J., Inyaku, K., Passaniti, A. & Capogrossi, M. C., Nov 27 1995, In : International Journal of Cancer. 63, 5, p. 673-679 7 p.

Research output: Contribution to journalArticle

60 Scopus citations

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial

Haas, N. B., Manola, J., Uzzo, R. G., Flaherty, K. T., Wood, C. G., Kane, C., Jewett, M., Dutcher, J. P., Atkins, M. B., Pins, M., Wilding, G., Cella, D., Wagner, L., Matin, S., Kuzel, T. M., Sexton, W. J., Wong, Y. N., Choueiri, T. K., Pili, R., Puzanov, I. & 5 others, Kohli, M., Stadler, W., Carducci, M., Coomes, R. & Dipaola, R. S., May 14 2016, In : The Lancet. 387, 10032, p. 2008-2016 9 p.

Research output: Contribution to journalArticle

294 Scopus citations

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer

Wentink, M. Q., Broxterman, H. J., Lam, S. W., Boven, E., Walraven, M., Griffioen, A. W., Pili, R., Van Der Vliet, H. J., De Gruijl, T. D. & Verheul, H. M. W., Oct 11 2016, In : British Journal of Cancer. 115, 8, p. 940-948 9 p.

Research output: Contribution to journalArticle

2 Scopus citations

A functional ryanodine-sensitive intracellular Ca2+ store is present in vascular endothelial cells

Ziegelstein, R. C., Spurgeon, H. A., Pili, R., Passaniti, A., Cheng, L., Corda, S., Lakatta, E. G. & Capogrossi, M. C., Jan 1 1994, In : Circulation research. 74, 1, p. 151-156 6 p.

Research output: Contribution to journalArticle

Open Access
47 Scopus citations

Ageing, Disability, and Spinal Cord Injury: Some Issues of Analysis

Pili, R., Gaviano, L., Pili, L. & Petretto, D. R., Jan 1 2018, In : Current Gerontology and Geriatrics Research. 2018, 4017858.

Research output: Contribution to journalReview article

2 Scopus citations

A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma

Zhao, M., Rudek, M. A., Mnasakanyan, A., Hartke, C., Pili, R. & Baker, S. D., Jan 17 2007, In : Journal of Pharmaceutical and Biomedical Analysis. 43, 2, p. 784-787 4 p.

Research output: Contribution to journalArticle

11 Scopus citations

Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma

Buck, M. J., Raaijmakers, L. M., Ramakrishnan, S., Wang, D., Valiyaparambil, S., Liu, S., Nowak, N. J. & Pili, R., Oct 9 2014, In : Oncogene. 33, 41, p. 4961-4965 5 p.

Research output: Contribution to journalArticle

11 Scopus citations

Altered angiogenesis underlying age-dependent changes in tumor growth

Pili, R., Guo, Y., Chang, J., Nakanishi, H., Martin, G. R. & Passaniti, A., Sep 7 1994, In : Journal of the National Cancer Institute. 86, 17, p. 1303-1314 12 p.

Research output: Contribution to journalArticle

110 Scopus citations

Androgen Receptor Modulation Optimized for Response (ARMOR) phase i and II studies: Galeterone for the treatment of castration-resistant prostate cancer

Montgomery, B., Eisenberger, M. A., Rettig, M. B., Chu, F., Pili, R., Stephenson, J. J., Vogelzang, N. J., Koletsky, A. J., Nordquist, L. T., Edenfield, W. J., Mamlouk, K., Ferrante, K. J. & Taplin, M. E., Mar 15 2016, In : Clinical Cancer Research. 22, 6, p. 1356-1363 8 p.

Research output: Contribution to journalArticle

48 Scopus citations

A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation

Lin, K. S., Luu, A., Baidoo, K. E., Hashemzadeh-Gargari, H., Chen, M. K., Brenneman, K., Pili, R., Pomper, M., Carducci, M. A. & Wagner, H. N., Jan 2005, In : Bioconjugate Chemistry. 16, 1, p. 43-50 8 p.

Research output: Contribution to journalArticle

57 Scopus citations

A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier

Lin, K. S., Luu, A., Baidoo, K. E., Hashemzadeh-Gargari, H., Chen, M. K., Pili, R., Pomper, M., Carducci, M. & Wagner, H. N., Nov 1 2004, In : Bioconjugate Chemistry. 15, 6, p. 1416-1423 8 p.

Research output: Contribution to journalArticle

19 Scopus citations

Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination

Keizman, D., Huang, P., Eisenberger, M. A., Pili, R., Kim, J. J., Antonarakis, E. S., Hammers, H. & Carducci, M. A., Sep 1 2011, In : European Journal of Cancer. 47, 13, p. 1955-1961 7 p.

Research output: Contribution to journalArticle

83 Scopus citations

An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer

Pili, R., Carducci, M., Brown, P. & Hurwitz, H., Dec 1 2014, In : Investigational New Drugs. 32, 6, p. 1258-1268 11 p.

Research output: Contribution to journalArticle

4 Scopus citations

Antitumor activity and mechanistic characterization of APE1/ReF-1 inhibitors in bladder cancer

Fishel, M. L., Xia, H., McGeown, J., McIlwain, D. W., Elbanna, M., Craft, A. A., Kaimakliotis, H. Z., Sandusky, G. E., Zhang, C., Pili, R., Kelley, M. R. & Jerde, T. J., 2019, In : Molecular cancer therapeutics. 18, 11, p. 1947-1960 14 p.

Research output: Contribution to journalArticle

2 Scopus citations

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models

Qian, D. Z., Wei, Y. F., Wang, X., Kato, Y., Cheng, L. & Pili, R., Aug 1 2007, In : Prostate. 67, 11, p. 1182-1193 12 p.

Research output: Contribution to journalArticle

51 Scopus citations

Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma

Kato, Y., Salumbides, B. C., Wang, X. F., Qian, D. Z., Williams, S., Wei, Y., Sanni, T. B., Atadja, P. & Pili, R., Jan 1 2007, In : Molecular cancer therapeutics. 6, 1, p. 70-81 12 p.

Research output: Contribution to journalArticle

47 Scopus citations

A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer

Morris, M. J., Eisenberger, M. A., Pili, R., Denmeade, S. R., Rathkopf, D., Slovin, S. F., Farrelly, J., Chudow, J. J., Vincent, M., Scher, H. I. & Carducci, M. A., Oct 2012, In : Annals of Oncology. 23, 10, p. 2714-2719 6 p., mds078.

Research output: Contribution to journalArticle

27 Scopus citations

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors

Michaelson, M. D., Gupta, S., Agarwal, N., Szmulewitz, R., Powles, T., Pili, R., Bruce, J. Y., Vaishampayan, U., Larkin, J., Rosbrook, B., Wang, E., Murphy, D., Wang, P., Lechuga, M. J., Valota, O. & Shepard, D. R., Sep 1 2019, In : Oncologist. 24, 9, p. 1151-e817

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer

Pili, R., Qin, R., Flynn, P. J., Picus, J., Millward, M., Ho, W. M., Pitot, H., Tan, W., Miles, K. M., Erlichman, C. & Vaishampayan, U., Dec 1 2013, In : Clinical Genitourinary Cancer. 11, 4, p. 477-483 7 p.

Research output: Contribution to journalArticle

50 Scopus citations

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal ® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)

Harrison, M. R., Hahn, N. M., Pili, R., Oh, W. K., Hammers, H., Sweeney, C., Kim, K. M., Perlman, S., Arnott, J., Sidor, C., Wilding, G. & Liu, G., Dec 1 2011, In : Investigational New Drugs. 29, 6, p. 1465-1474 10 p.

Research output: Contribution to journalArticle

63 Scopus citations

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

Bruce, J. Y., Eickhoff, J., Pili, R., Logan, T., Carducci, M., Arnott, J., Treston, A., Wilding, G. & Liu, G., Apr 2012, In : Investigational New Drugs. 30, 2, p. 794-802 9 p.

Research output: Contribution to journalArticle

51 Scopus citations

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

Heath, E. I., Gaskins, M., Pitot, H. C., Pili, R., Tan, W., Marschke, R., Liu, G., Hillman, D., Sarkar, F., Sheng, S., Erlichman, C. & Ivy, P., Sep 2005, In : Clinical Prostate Cancer. 4, 2, p. 138-141 4 p.

Research output: Contribution to journalArticle

48 Scopus citations

A Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

Heath, E. I., Hillman, D. W., Vaishampayan, U., Sheng, S., Sarkar, F., Harper, F., Gaskins, M., Pitot, H. C., Tan, W., Ivy, S. P., Pili, R., Carducci, M. A., Erlichman, C. & Liu, G., Dec 1 2008, In : Clinical Cancer Research. 14, 23, p. 7940-7946 7 p.

Research output: Contribution to journalArticle

137 Scopus citations

A Phase II Trial of Temozolomide and IFN-α in Patients with Advanced Renal Cell Carcinoma

Sunkara, U., Walczak, J. R., Summerson, L., Rogers, T., Eisenberger, M., Denmeade, S., Pili, R., Huff, C. A., Sinibaldi, V. & Carducci, M. A., Jan 1 2004, In : Journal of Interferon and Cytokine Research. 24, 1, p. 37-41 5 p.

Research output: Contribution to journalArticle

10 Scopus citations

A Phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone

Resta, L. P., Pili, R., Eisenberger, M. A., Spitz, A., King, S., Porter, J., Franke, A., Boinpally, R., Carducci, M. A. & Sweeney, C. J., Feb 2011, In : Cancer Chemotherapy and Pharmacology. 67, 2, p. 431-438 8 p.

Research output: Contribution to journalArticle

1 Scopus citations

A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805])

Pili, R., Jegede, O., Carducci, M. A., Manola, J., Groteluschen, D. L., Appleman, L. L., Liu, G., Shanks, J. C., Dakhil, S. R., Dutcher, J. & DiPaola, R. S., Dec 2017, In : Clinical Genitourinary Cancer. 15, 6, p. 642-651.e1

Research output: Contribution to journalArticle

Assay, isolation and characterization of circulating immune complexes from serum of gastrointestinal cancer, stage iii and iv melanoma and chronic inflammatory bowel disease patients

Bartoloni, C., Guidi, L., Pili, R., Lewis, Z. A., Tricerri, A., Cursi, F., Gentiioni, N., Cortesi, E. & Gambassi, G., Jan 1 1987, In : Oncology (Switzerland). 50, 1, p. 27-34 8 p.

Research output: Contribution to journalArticle

7 Scopus citations

Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)1A.J.A. and R.K. contributed equally to this work

Armstrong, A. J., Kaboteh, R., Carducci, M. A., Damber, J. E., Stadler, W. M., Hansen, M., Edenbrandt, L., Forsberg, G., Nordle, Ö., Pili, R. & Morris, M. J., 2014, In : Urologic Oncology: Seminars and Original Investigations. 32, 8, p. 1308-1316 9 p.

Research output: Contribution to journalArticle

35 Scopus citations

Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma

Keizman, D., Ish-Shalom, M., Pili, R., Hammers, H., Eisenberger, M. A., Sinibaldi, V., Boursi, B., Maimon, N., Gottfried, M., Hayat, H., Peer, A., Kovel, S., Sella, A., Berger, R. & Carducci, M. A., May 1 2012, In : European Journal of Cancer. 48, 7, p. 1031-1037 7 p.

Research output: Contribution to journalArticle

42 Scopus citations

Bisphosphonates in renal cell carcinoma: Palliation versus antitumor effects

George, S. & Pili, R., Oct 1 2011, Targeted Therapies for Renal Cell Carcinoma. Future Medicine Ltd., p. 121-125 5 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

Cancer of the Kidney

Pili, R., Kauffman, E. & Rodriguez, R., Jan 1 2014, Abeloff's Clinical Oncology: Fifth Edition. Elsevier Inc., p. 1416-1444.e5

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations

Can post-transcription modifiers change the course of prostate cancer?

Qian, D. Z. & Pili, R., Apr 19 2016, Prostate Cancer: Translational and Emerging Therapies. CRC Press, p. 179-194 16 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-ribose) polymerase inhibitors, and PD-1 inhibitors

Antonarakis, E. S., Velho, P. I., Fu, W., Wang, H., Agarwal, N., Santos, V. S., Maughan, B. L., Pili, R., Adra, N., Sternberg, C. N., Vlachostergios, P. J., Tagawa, S. T., Bryce, A. H., McNatty, A. L., Reichert, Z. R., Dreicer, R., Sartor, O., Lotan, T. L. & Hussain, M., 2019, In : JCO Precision Oncology. 3, p. 370-381 12 p.

Research output: Contribution to journalArticle

CEP-7055: A novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models

Ruggeri, B., Singh, J., Gingrich, D., Angeles, T., Albom, M., Chang, H., Robinson, C., Hunter, K., Dobrzanski, P., Jones-Bolin, S., Aimone, L., Klein-Szanto, A., Herbert, J. M., Bono, F., Schaeffer, P., Casellas, P., Bourie, B., Pili, R., Isaacs, J., Ator, M. & 4 others, Hudkins, R., Vaught, J., Mallamo, J. & Dionne, C., Sep 15 2003, In : Cancer Research. 63, 18, p. 5978-5991 14 p.

Research output: Contribution to journalArticle

111 Scopus citations

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

Shen, L. & Pili, R., Dec 1 2012, In : OncoImmunology. 1, 6, p. 948-950 3 p.

Research output: Contribution to journalArticle

21 Scopus citations

Class I Histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models

Shen, L., Ciesielski, M., Ramakrishnan, S., Miles, K. M., Ellis, L., Sotomayor, P., Shrikant, P., Fenstermaker, R. & Pili, R., Jan 27 2012, In : PloS one. 7, 1, e30815.

Research output: Contribution to journalArticle

100 Scopus citations

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α

Qian, D. Z., Kachhap, S. K., Collis, S. J., Verheul, H. M. W., Carducci, M. A., Atadja, P. & Pili, R., Sep 1 2006, In : Cancer Research. 66, 17, p. 8814-8821 8 p.

Research output: Contribution to journalArticle

242 Scopus citations

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers

Radovich, M., Kiel, P. J., Nance, S. M., Niland, E. E., Parsley, M. E., Ferguson, M. E., Jiang, G., Ammakkanavar, N. R., Einhorn, L. H., Cheng, L., Nassiri, M., Davidson, D. D., Rushing, D. A., Loehrer, P. J., Pili, R., Hanna, N., Thomas Callaghan, J., Skaar, T. C., Helft, P. R., Shahda, S. & 2 others, O'Neil, B. H. & Schneider, B. P., 2016, In : Oncotarget. 7, 35, p. 56491-56500 10 p.

Research output: Contribution to journalArticle

38 Scopus citations

Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation

Wang, J., Papanicolau-Sengos, A., Chintala, S., Wei, L., Liu, B., Hu, Q., Miles, K. M., Conroy, J. M., Glenn, S. T., Costantini, M., Magi-Galluzzi, C., Signoretti, S., Choueiri, T., Gallucci, M., Sentinelli, S., Fazio, V. M., Poeta, M. L., Liu, S., Morrison, C. & Pili, R., May 24 2016, In : Oncotarget. 7, 21, p. 29901-29915 15 p.

Research output: Contribution to journalArticle

20 Scopus citations

Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells

Kato, Y., Yoshino, I., Egusa, C., Maeda, T., Pili, R. & Tsuboi, R., Aug 2014, In : Journal of Dermatological Science. 75, 2, p. 140-147 8 p.

Research output: Contribution to journalArticle

14 Scopus citations

Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis

Pili, R., Kruszewski, M. P., Hager, B. W., Lantz, J. & Carducci, M. A., Feb 15 2001, In : Cancer Research. 61, 4, p. 1477-1485 9 p.

Research output: Contribution to journalArticle

114 Scopus citations

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: A multicentre, single-arm phase I/II clinical trial

Pili, R., Liu, G., Chintala, S., Verheul, H., Rehman, S., Attwood, K., Lodge, M. A., Wahl, R., Martin, J. I., Miles, K. M., Paesante, S., Adelaiye, R., Godoy, A., King, S., Zwiebel, J. & Carducci, M. A., Mar 28 2017, In : British Journal of Cancer. 116, 7, p. 874-883 10 p.

Research output: Contribution to journalArticle

30 Scopus citations

Combination strategy targeting the hypoxia inducible factor-1 α with mammalian target of rapamycin and histone deacetylase inhibitors

Verheul, H. M. W., Salumbides, B., Van Erp, K., Hammers, H., Qian, D. Z., Sanni, T., Atadja, P. & Pili, R., Jun 1 2008, In : Clinical Cancer Research. 14, 11, p. 3589-3597 9 p.

Research output: Contribution to journalArticle

95 Scopus citations

Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models

Ciamporcero, E., Miles, K. M., Adelaiye, R., Ramakrishnan, S., Shen, L., Ku, S. Y., Pizzimenti, S., Sennino, B., Barrera, G. & Pili, R., Jan 1 2015, In : Molecular cancer therapeutics. 14, 1, p. 101-110 10 p.

Research output: Contribution to journalArticle

58 Scopus citations

Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer

Ellis, L., Ku, S. Y., Ramakrishnan, S., Lasorsa, E., Azabdaftari, G., Godoy, A. & Pili, R., Dec 2013, In : Oncotarget. 4, 12, p. 2225-2236 12 p.

Research output: Contribution to journalArticle

Open Access
49 Scopus citations

Concordance of cancer patients' function, symptoms, and supportive care needs

Snyder, C. F., Garrett-Mayer, E., Blackford, A. L., Brahmer, J. R., Carducci, M. A., Pili, R., Stearns, V., Wolff, A. C., Dy, S. M. & Wu, A. W., Oct 1 2009, In : Quality of Life Research. 18, 8, p. 991-998 8 p.

Research output: Contribution to journalArticle

32 Scopus citations